Blood Collection Device Market Report 2034

Report Description

This report is updated with the latest market data and insights as of June 2026. Base year: 2025  |  Forecast period: 2026-2034

Blood Collection Device Market Outlook

According to our latest research, the global blood collection device market size reached USD 8.5 billion in 2025, reflecting robust demand across healthcare and diagnostics sectors worldwide. The market is expected to grow at a CAGR of 6.7% during the forecast period from 2026 to 2034, reaching a projected value of USD 15.2 billion by 2034. This growth is primarily fueled by the rising prevalence of chronic diseases, increased healthcare expenditure across both developed and emerging economies, and continuous technological advancements in blood collection methodologies. As per our most recent analysis, the market continues to benefit from the expanding application of blood-based diagnostics and the global emphasis on strengthening healthcare infrastructure in the post-pandemic environment.

Get Free Sample Report

One of the primary growth drivers for the blood collection device market is the escalating incidence of chronic and infectious diseases worldwide. The surge in conditions such as diabetes, cardiovascular diseases, and various forms of cancer has led to a significant increase in the number of diagnostic procedures, most of which require efficient and safe blood collection. The growing geriatric population, which is more susceptible to these conditions, further amplifies demand. The persistent threat of emerging infectious diseases has reinforced the critical role of blood collection in rapid diagnostics and epidemiological surveillance, thereby sustaining market growth well into the 2026-2034 forecast horizon. The global blood collection industry is evolving rapidly as procurement models and device standards adapt to these healthcare pressures.

Technological advancements and product innovation constitute another major growth factor. Manufacturers are investing heavily in research and development to introduce devices that enhance patient comfort, minimize the risk of needlestick injuries, and ensure accurate sample collection. The advent of safety-engineered devices, vacuum-based collection tubes, and automated blood collection systems has revolutionized the industry by improving efficiency and reducing contamination risks. These innovations are particularly important in high-volume healthcare settings, where speed, safety, and reliability are paramount. Furthermore, the integration of digital technologies for sample tracking and data management has streamlined laboratory workflow and reduced pre-analytical errors, contributing significantly to market expansion.

The growing emphasis on preventive healthcare and routine health screenings is also significantly boosting the market. Governments and healthcare organizations are increasingly promoting early detection programs for various diseases, which often rely on blood-based diagnostics. This trend is especially prominent in developed regions, where healthcare systems are well-equipped to implement widespread screening initiatives. Additionally, the expansion of healthcare infrastructure in emerging economies is facilitating greater access to diagnostic services, increasing adoption of blood collection devices. The rise in point-of-care testing and home healthcare services further broadens the market scope. Capillary blood self-collection devices in particular are gaining traction as patients and providers seek minimally invasive, convenient sampling solutions outside traditional clinical environments.

In recent years, the introduction of blood-draw assistant robots has marked a significant advancement in the field of blood collection. These systems utilize advanced imaging and sensor technologies to accurately locate veins, reducing the likelihood of multiple needle insertions and improving patient comfort. By automating the blood draw process, these robots minimize the risk of needlestick injuries to healthcare workers while ensuring consistent sample quality. As healthcare facilities continue to adopt automation to streamline operations, robotic blood draw systems are poised to become an integral part of modern medical practice, contributing to the overall growth and diversification of the blood collection device market through 2034.

Regionally, North America continues to dominate the blood collection device market, accounting for approximately 37.2% of total revenue in 2025. This is attributed to advanced healthcare infrastructure, high awareness of blood safety protocols, and significant investments in healthcare technology. Europe follows closely, benefiting from supportive regulatory frameworks and robust healthcare systems. Meanwhile, the Asia Pacific region is emerging as the fastest-growing market, driven by a large patient pool, increasing healthcare expenditure, and rapid adoption of modern diagnostic techniques. Latin America and the Middle East and Africa are also witnessing steady growth, supported by improving healthcare access and rising demand for diagnostic services across both public and private sectors.

Product Type Analysis

The blood collection device market is segmented by product type into needles and syringes, blood collection tubes, blood bags, lancets, and others. Among these, needles and syringes represent the largest segment in terms of revenue, accounting for approximately 34.5% of the market in 2025, owing to their indispensable role in both manual and automated blood collection. The widespread use of safety-engineered needles and syringes, designed to prevent needlestick injuries and cross-contamination, has become a standard in hospitals and clinics worldwide. Manufacturers are increasingly focusing on ergonomic designs and single-use disposable products to enhance patient safety and convenience, further driving growth in this category through the forecast period.

Get Free Sample Report

Blood collection tubes constitute another significant segment, accounting for approximately 27.8% of the market in 2025, and witnessing robust demand due to their critical role in preserving sample integrity during transportation and analysis. These tubes are available in various types, including EDTA, heparin, citrate, and serum-separating variants, each tailored for specific diagnostic applications. The shift toward vacuum-based collection systems has improved sample accuracy and reduced hemolysis, making these tubes a preferred choice in clinical laboratories. As diagnostic testing becomes more sophisticated and diversified, the need for specialized blood collection tubes is expected to rise steadily, bolstering segment growth through 2034.

The blood bags segment, holding around 18.2% of the 2025 market, is primarily driven by the growing demand for blood transfusions and the expansion of blood bank networks globally. These bags are essential for the collection, storage, and transportation of blood and its components. Technological advancements, such as the development of multi-bag systems and integrated filters, have enhanced the safety and efficiency of blood collection processes. The increasing frequency of surgical procedures, trauma cases, and the prevalence of anemia and other blood disorders are key factors sustaining demand for blood bags across both developed and developing markets.

Lancets account for approximately 12.6% of the 2025 market and are gaining significant traction, particularly in point-of-care and home healthcare settings. Lancets are widely used for capillary blood sampling, especially in diabetic care for glucose monitoring. Advances in lancet design, including ultra-thin needles and automatic retraction mechanisms, have improved patient comfort and minimized pain during sampling. The rise in self-monitoring practices and decentralized diagnostic approaches is expected to drive adoption of these devices. The growing scope of self-collection tools for capillary sampling is further reinforcing demand across home and community health settings. Other products, including micro-collection devices and safety accessories, cater to niche applications and contribute to the overall diversity of the market.

The competitive landscape within each product type segment is characterized by continuous innovation and the introduction of next-generation devices that prioritize safety, efficiency, and user-friendliness. Regulatory compliance and adherence to international safety standards remain critical for market players, as healthcare providers increasingly prioritize products that minimize risks to both patients and healthcare workers. As demand for blood collection devices continues to grow through 2034, companies are expected to focus on expanding their product portfolios and enhancing distribution networks to capitalize on emerging opportunities in both established and high-growth markets.

Report Scope

Method Analysis

The blood collection device market is segmented by method into manual blood collection and automated blood collection. Manual blood collection remains the predominant method, especially in developing regions where resource constraints and limited access to advanced technologies persist. This method typically involves the use of needles, syringes, and collection tubes, and is widely adopted in hospitals, clinics, and smaller diagnostic centers. Despite the simplicity and cost-effectiveness of manual blood collection, there are inherent challenges such as variability in sample quality, risk of contamination, and increased potential for needlestick injuries. These limitations have prompted a gradual but accelerating shift toward more advanced methods in developed markets over the 2019-2025 historical period, a trend expected to continue through 2034.

Automated blood collection systems are gaining significant traction, particularly in high-volume healthcare settings and advanced laboratories. These systems utilize vacuum-assisted devices, integrated sample tracking, and automated labeling to streamline the collection process, reduce human error, and enhance sample integrity. The adoption of automation is driven by the need for greater efficiency, higher throughput, and improved safety in blood collection procedures. Automated systems also facilitate better compliance with regulatory standards and enable seamless integration with laboratory information management systems (LIMS), making them a preferred choice in large hospitals and reference laboratories across North America, Europe, and increasingly in Asia Pacific.

The transition from manual to automated blood collection methods is further accelerated by the increasing emphasis on infection control and occupational safety. Automated devices are designed to minimize direct contact with blood samples, thereby reducing the risk of exposure to infectious agents for healthcare workers. The lessons learned from the COVID-19 pandemic regarding workflow continuity and frontline staff safety have led to sustained investments in automated blood collection technologies through 2025. As healthcare providers continue to prioritize safety and efficiency, the adoption of automated systems is expected to rise steadily over the 2026-2034 forecast period, particularly as device costs decline and digital integration capabilities improve.

Despite the clear advantages of automation, the high initial investment and maintenance costs associated with automated blood collection systems remain a barrier for widespread adoption, particularly in resource-limited settings across Latin America, Africa, and parts of South and Southeast Asia. Manual blood collection continues to hold a significant share of the market due to its affordability and ease of use. However, ongoing efforts to reduce the cost of automation, coupled with government initiatives to modernize healthcare infrastructure, are expected to bridge this gap progressively through the forecast period. The coexistence of both methods highlights the diverse needs and resource availability across different regions and end-user segments.

Manufacturers are increasingly offering hybrid solutions that combine the benefits of manual and automated blood collection methods, providing flexibility and scalability to healthcare providers of varying sizes and resource levels. The integration of smart technologies such as barcode scanning, RFID tagging, and digital data capture into both manual and automated devices is further enhancing workflow efficiency and end-to-end sample traceability. As the market continues to evolve through 2034, the method segment is expected to witness significant innovation and diversification, driven by the dual imperatives of patient safety and operational excellence in healthcare delivery.

Application Analysis

The blood collection device market is segmented by application into diagnostics, therapeutics, and research. The diagnostics segment dominates the market, accounting for the largest share in 2025. This is primarily due to the widespread use of blood-based tests for disease detection, monitoring, and management across a broad spectrum of conditions. Blood collection is a fundamental step in diagnostic workflows for infectious diseases, metabolic disorders, hematological abnormalities, and cancer screening programs. The increasing prevalence of chronic diseases and the growing emphasis on early detection and preventive healthcare are driving sustained demand for diagnostic blood collection devices through the 2026-2034 forecast period.

The therapeutics segment is also experiencing steady growth, fueled by the rising number of blood transfusions, plasma therapies, and stem cell treatments. Blood collection devices are essential for the safe and efficient collection of blood and its components for therapeutic purposes. The expansion of blood banks and transfusion centers, coupled with advancements in apheresis technology, has enhanced the efficiency and safety of therapeutic blood collection processes. The growing incidence of conditions requiring transfusion support, including trauma, major surgeries, and hematological disorders such as sickle cell disease and thalassemia, is expected to sustain strong demand in this segment globally.

Research applications represent a significant and growing segment within the blood collection device market. Blood samples are indispensable in biomedical research, clinical trials, and the development of new diagnostic and therapeutic modalities. The increasing focus on personalized medicine, genomics, proteomics, and biomarker discovery has intensified the need for high-quality blood samples and advanced collection devices that ensure pre-analytical integrity. Research laboratories and academic-affiliated institutions are investing in state-of-the-art blood collection technologies to support reproducible and scientifically rigorous outcomes, thereby contributing to market growth in this segment through 2034.

The diversification of applications for blood collection devices is a key factor driving market expansion. The emergence of novel diagnostic platforms such as liquid biopsy and next-generation point-of-care testing has created new opportunities for device manufacturers to develop specialized collection solutions. These platforms require devices that can accommodate small sample volumes and ensure compatibility with advanced analytical techniques including mass spectrometry and next-generation sequencing. The integration of blood collection devices with digital health solutions and cloud-based data management platforms is further enhancing their utility in both clinical and research settings. The expanding scope of sample collection device applications beyond human medicine also demonstrates the broader innovation trajectory shaping this space.

As the landscape of healthcare and biomedical research continues to evolve, the application segment of the blood collection device market is expected to witness sustained growth and innovation through 2034. Manufacturers are focusing on developing versatile and adaptable devices that can meet the diverse needs of diagnostics, therapeutics, and research. Increasing collaboration between healthcare providers, research institutions, contract research organizations, and industry stakeholders is expected to drive further advancements and foster the development of next-generation blood collection solutions tailored to specific application requirements.

End-User Analysis

The blood collection device market is segmented by end-user into hospitals and clinics, diagnostic centers, blood banks, research laboratories, and others. Hospitals and clinics constitute the largest end-user segment, accounting for a significant share of the market in 2025. These facilities perform a high volume of blood collection procedures for both diagnostic and therapeutic purposes on a daily basis. The increasing patient inflow resulting from rising disease burden, expansion of hospital infrastructure particularly in Asia Pacific and the Middle East, and adoption of advanced medical technologies are key factors driving demand for blood collection devices in this segment. Hospitals and clinics also prioritize safety and regulatory compliance, prompting adoption of innovative safety-engineered devices.

Diagnostic centers represent another major end-user segment, driven by the growing demand for laboratory testing and preventive health screenings. The proliferation of standalone diagnostic centers and chain laboratory networks, particularly in urban and peri-urban areas, has increased the volume of blood collection procedures across global markets. These centers require reliable and efficient devices to ensure accurate sample collection and timely reporting of results. The trend toward decentralized diagnostics and the rise of point-of-care testing are expected to further boost demand for blood collection devices in this segment through the forecast period ending 2034.

Blood banks are critical end-users of blood collection devices, responsible for the collection, processing, storage, and distribution of blood and its components to healthcare facilities. The increasing number of voluntary blood donation drives, expansion of blood bank networks in emerging economies, and rising public awareness of blood safety have contributed to consistent growth of this segment. Blood banks require specialized devices such as blood bags with integrated leukoreduction filters and automated apheresis collection systems to ensure the safety and quality of collected blood. The growing demand for blood transfusions and fractionated plasma therapies is expected to sustain demand in this segment through 2034.

Research laboratories, including pharmaceutical companies, contract research organizations, and academic medical centers, are emerging as important and faster-growing end-users of blood collection devices. These facilities rely on high-quality blood samples for a wide range of activities including biomarker discovery, drug development, clinical trials, and epidemiological studies. The increasing investment in biomedical research and the growing focus on personalized medicine and companion diagnostics are driving demand for advanced blood collection devices that guarantee sample integrity. Manufacturers are responding by developing specialized devices meeting the stringent quality and traceability requirements of regulated research environments.

Other end-users, including home healthcare providers, mobile health units, employer wellness programs, and public health agencies, also contribute meaningfully to demand for blood collection devices. The rise of home-based diagnostics and telehealth platforms has created new opportunities for device manufacturers to develop user-friendly, portable, and minimally invasive blood collection solutions. As healthcare delivery models continue to evolve toward decentralization and patient empowerment, the end-user landscape of the blood collection device market is expected to become increasingly diverse, with growing emphasis on accessibility, safety, and convenience across care settings.

Opportunities and Threats

The blood collection device market presents several significant opportunities for growth and innovation through 2034. The increasing adoption of point-of-care testing and home healthcare services is creating new avenues for device manufacturers to develop compact, easy-to-use, and minimally invasive blood collection solutions. The integration of digital technologies such as barcode scanning, RFID tracking, and AI-assisted data analytics is enhancing sample traceability and improving workflow efficiency across the care continuum. Additionally, the growing focus on personalized medicine and precision diagnostics is driving demand for specialized blood collection devices that accommodate small sample volumes and ensure compatibility with advanced analytical platforms. Emerging markets in Asia Pacific, Latin America, and the Middle East and Africa offer substantial growth potential due to rising healthcare expenditure, expanding infrastructure, and increasing awareness of preventive healthcare among growing middle-class populations.

Another major opportunity lies in the development of safety-engineered and eco-friendly blood collection devices. The increasing global emphasis on infection control and occupational safety is prompting healthcare providers to adopt devices that minimize the risk of needlestick injuries and cross-contamination. Manufacturers are investing in single-use, disposable, and recyclable product lines to address environmental concerns and comply with stringent regulatory requirements in markets including the European Union and North America. The expansion of blood donation programs and the growing need for blood transfusions in trauma care, complex surgeries, and chronic disease management are expected to further drive demand for innovative blood collection solutions. Strategic collaborations between industry players, healthcare organizations, and regulatory bodies are also fostering the development and broader adoption of next-generation devices.

Despite the numerous opportunities, the blood collection device market faces certain restraints and challenges. One of the primary threats is the high cost of advanced blood collection devices, particularly fully automated systems, which can significantly limit adoption in resource-constrained settings across developing regions. The persistent risk of sample contamination, hemolysis, and needlestick injuries in facilities with inadequate training and safety protocols remains a concern affecting sample quality and healthcare worker safety. Regulatory compliance and adherence to international quality standards can pose entry barriers for manufacturers seeking to expand into new markets with divergent approval processes. The presence of counterfeit and substandard products in certain regions also threatens market integrity and patient safety. Addressing these challenges will require continued investment in training, education, cost reduction strategies, and the development of reliable blood collection solutions accessible across all healthcare settings.

Regional Outlook

North America remains the dominant region in the global blood collection device market, accounting for approximately USD 3.2 billion in revenue in 2025 and representing roughly 37.2% of the global market share. The region benefits from advanced healthcare infrastructure, high awareness of blood safety protocols, and significant investments in research and development. The presence of leading market players and a well-established regulatory framework further support market growth. The United States is the primary contributor, driven by the high prevalence of chronic diseases, extensive healthcare coverage, and rapid adoption of cutting-edge diagnostic technologies. The North America market is expected to grow at a steady CAGR of 6.1% during the forecast period, reaching an estimated value of USD 5.6 billion by 2034.

Get Free Sample Report

Europe follows as the second-largest regional market, with a market size of approximately USD 2.3 billion in 2025, representing around 27.6% of global revenue. The region is characterized by robust healthcare systems, supportive government initiatives, and a strong focus on preventive healthcare and early disease detection. Countries including Germany, France, and the United Kingdom are leading adopters of advanced blood collection devices, driven by high healthcare expenditure and a growing emphasis on patient and worker safety. The European market is also benefiting from the expansion of diagnostic and translational research activities. The market in Europe is projected to reach USD 4.1 billion by 2034, growing at a CAGR of 6.4%.

The Asia Pacific region is the fastest-growing market for blood collection devices globally, with a market size of approximately USD 1.8 billion in 2025, representing around 21.4% of global revenue. Rapid urbanization, increasing healthcare investment, and the expansion of both public and private healthcare infrastructure are key drivers of growth. Countries including China, India, Japan, and South Korea are witnessing a surge in demand for blood collection devices, fueled by large patient populations, rising awareness of preventive healthcare, and accelerating adoption of modern diagnostic techniques. The Asia Pacific market is expected to grow at a CAGR of 8.3%, reaching an estimated value of USD 3.7 billion by 2034. Latin America and the Middle East and Africa, accounting for approximately 7.9% and 5.9% of the 2025 market respectively, are also experiencing steady growth supported by improving healthcare access, increasing government health investments, and rising demand for diagnostic and therapeutic blood collection services across both regions.

Competitor Outlook

The blood collection device market is highly competitive, with a diverse array of global and regional players vying for market share across product categories, geographies, and end-user segments. The competitive landscape is characterized by continuous innovation, strategic partnerships, and a strong focus on safety and regulatory compliance. Leading companies are investing heavily in research and development to introduce next-generation devices that enhance patient comfort, minimize occupational risks, and streamline workflow. Product differentiation, technological advancements, and robust global distribution networks are key strategies employed by market players to maintain competitive advantage. The market also witnesses frequent mergers, acquisitions, and licensing agreements, as companies seek to expand product portfolios and strengthen presence in high-growth emerging markets.

The entry of innovative startups and the emergence of technology-driven challengers are intensifying competition in the blood collection device market. These companies are leveraging advanced technologies including automation, digital integration, AI-assisted vein detection, and eco-friendly materials to address unmet needs and capture niche segments. Regulatory compliance and adherence to international quality standards such as ISO 23908 and FDA safety device requirements remain critical for all market participants, as healthcare providers prioritize products that ensure safety and reliability. The presence of substandard products in developing regions poses an ongoing challenge to established players, necessitating investments in brand integrity, pharmacovigilance, and supply chain transparency.

Major companies in the blood collection device market include Becton, Dickinson and Company (BD), Terumo Corporation, Greiner Bio-One International GmbH, Fresenius Kabi AG, and Sarstedt AG and Co. KG. BD is a global leader, renowned for its comprehensive portfolio of blood collection needles, syringes, and safety-engineered devices. The company's commitment to innovation and quality has solidified its position as a preferred supplier to hospitals, clinics, and laboratories worldwide. Terumo Corporation is another key player, offering a wide range of blood collection and transfusion products with a strong focus on safety and operational efficiency across global markets.

Greiner Bio-One International GmbH specializes in blood collection tubes and accessories, catering to the needs of clinical laboratories and research institutions globally, with a particularly strong presence in Europe. Fresenius Kabi AG has a significant footprint in therapeutic blood collection and transfusion medicine, supported by its broad portfolio of blood bags and apheresis products. Sarstedt AG and Co. KG is recognized for innovative blood collection systems and a commitment to sustainability, offering a comprehensive range of products for clinical and research applications. Haemonetics Corporation is a leader in blood management solutions, particularly in automated apheresis and blood bank technologies.

Other notable players in the market include ICU Medical Inc., Nipro Medical Corporation, Macopharma SA, Grifols S.A., Abbott Laboratories, Cardinal Health Inc., FL Medical S.r.l., Retractable Technologies Inc., Weigao Group, and Sekisui Medical Co. Ltd. These companies are actively expanding their product portfolios, enhancing manufacturing capabilities, and exploring new market opportunities through strategic alliances and targeted acquisitions. The competitive outlook for the blood collection device market remains dynamic through 2034, with ongoing technological advances, evolving regulatory requirements, and shifting global healthcare priorities shaping the future of the industry.

Key Players

• Becton, Dickinson and Company (BD)
• Terumo Corporation
• Greiner Bio-One International GmbH
• Fresenius Kabi AG
• Haemonetics Corporation
• Nipro Medical Corporation
• Sarstedt AG & Co. KG
• ICU Medical, Inc.
• Macopharma SA
• Grifols, S.A.
• Abbott Laboratories
• Retractable Technologies, Inc.
• Cardinal Health, Inc.
• FL Medical S.r.l.
• Weigao Group
• Improve Medical Instruments Co., Ltd.
• Sekisui Medical Co., Ltd.
• JMS Co., Ltd.